This article only represents the author's own views.
Covid-related revenue streams are running dry at Fosun Pharmaceutical (Group) Co. Ltd (2196.HK; 600196.SH), but the company is shoring up its financial health with sales of other innovative drugs and medical services.
The latest earnings figures show Fosun Pharma is feeling some pain without a big “Covid dividend” from its sales of the comirnaty vaccine and the anti-viral drug azvudine. The company turned in a mixed bag of results last Tuesday, as first-half revenues rose just 0.16% to about 21.3 billion yuan ($2.92 billion) from the same period a year earlier, while income from products unrelated to Covid jumped around 15%.
您已閱讀11%（683字），剩余89%（5380字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。